Lab In The news

Experimental therapy for brain cancer gives ‘hope’; will be investigated in upcoming trial

April 4, 2025 The article describes how a groundbreaking immunotherapy regimen developed from melanoma research significantly extended the life of Dr. Richard Scolyer, who was diagnosed with glioblastoma and given just months to live. He received a novel combination of immune checkpoint inhibitors prior to surgery, followed by radiation, adjuvant immunotherapy, and a personalized peptide […]
Read more

Michael Bolton Brain Cancer: What Is Glioblastoma, What Are the Symptoms and Can You Prevent It?

May 1, 2025 This article discusses the diagnosis and ongoing battle of singer Michael Bolton against glioblastoma. At 72, Bolton began experiencing memory issues and balance problems, which led to an MRI revealing a brain tumor. After undergoing emergency surgery, radiation, and chemotherapy, Bolton’s most recent scan showed no signs of recurrence, but his journey […]
Read more

Clinical Trials Are Moving Out of the Lab and Into People’s Homes

February 18, 2021 This New York Times article highlights how the pandemic significantly disrupted clinical trials, leading to the suspension or termination of thousands of studies due to safety concerns and logistical challenges. In response, many researchers adapted by implementing remote monitoring, telehealth consultations, and home delivery of medications. Dr. Khasraw was featured and emphasized […]
Read more

New study highlights telehealth struggles in cancer care

March 17, 2023 A 2023 study explored the significant stress cancer patients experienced during the COVID-19 pandemic, particularly due to restrictions that prevented informal caregivers or support persons from attending appointments and treatments. The research highlighted how these restrictions, combined with the shift to telehealth, led to increased social isolation and a loss of vital […]
Read more

Injection Immunotherapies Get FDA Approval

February 10, 2025 This article describes how Tecentriq Hybreza (atezolizumab and hyaluronidase) became the first injectable anti-PD-L1 immunotherapy approved by the FDA, followed by the December approval of Opdivo Qvantig (nivolumab and hyaluronidase) to treat a range of cancers including melanoma, lung, liver, and skin cancers. Clinical trials showed similar effectiveness between injection and infusion […]
Read more

Integrated Proteogenomic Characterization of Glioblastoma Evolution: Overcoming Barriers to Develop Personalized Treatment Strategies

March 19, 2025 This article highlights how one reason for limited progress in glioblastoma treatment in recent years is the lack of understanding of tumor behavior at the proteomic and spatial levels. Integrated proteogenomic characterization—combining genomics, transcriptomics, and proteomics—has emerged as a promising approach to identify patient-specific molecular signatures. These insights can be used to […]
Read more

Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy

April 24, 2025 Siren Biotechnology at UCSF is developing the first universal AAV-based gene therapy for solid tumors, starting with brain cancers like high-grade gliomas. To fund its upcoming first-in-human clinical trial, Siren launched a community investment round via Wefunder, seeking $50,000–$5 million. Its lead therapy, SRN-101, combines gene therapy with cytokine immunotherapy and has […]
Read more